CHEMOMAB THERAPEUTICS LTD's ticker is CMMB and the CUSIP is 16385C104. A total of 12 filers reported holding CHEMOMAB THERAPEUTICS LTD in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,587 | -55.7% | 1,775 | -34.9% | 0.00% | – |
| Q2 2023 | $3,580 | -17.3% | 2,725 | 0.0% | 0.00% | – |
| Q1 2023 | $4,330 | -79.4% | 2,725 | -57.2% | 0.00% | – |
| Q4 2022 | $21,000 | +16.7% | 6,374 | -8.8% | 0.00% | – |
| Q3 2022 | $18,000 | -37.9% | 6,987 | -9.6% | 0.00% | – |
| Q2 2022 | $29,000 | -14.7% | 7,728 | +8.2% | 0.00% | – |
| Q1 2022 | $34,000 | +9.7% | 7,144 | +62.7% | 0.00% | – |
| Q4 2021 | $31,000 | -94.9% | 4,390 | -92.0% | 0.00% | -100.0% |
| Q3 2021 | $608,000 | – | 54,821 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,578,174 | $12,375,000 | 0.20% |
| Ikarian Capital, LLC | 268,104 | $1,292,000 | 0.17% |
| Cormorant Asset Management, LP | 288,168 | $1,383,000 | 0.11% |
| BOOTHBAY FUND MANAGEMENT, LLC | 41,298 | $198,000 | 0.01% |
| MEITAV INVESTMENT HOUSE LTD | 35,024 | $167,000 | 0.00% |
| Newbridge Financial Services Group, Inc. | 1,100 | $5,000 | 0.00% |
| ENVESTNET ASSET MANAGEMENT INC | 10,807 | $52,000 | 0.00% |
| JPMORGAN CHASE & CO | 753 | $4,000 | 0.00% |
| Renaissance Technologies | 27,960 | $134,000 | 0.00% |
| ARK Investment Management | 792 | $4,000 | 0.00% |